Re: Farmas USA
Re: Farmas USA
Endocyte Announces Late-Breaking Abstract Presentation at the European Society for Medical Oncology (ESMO) Conference
WEST LAFAYETTE, Ind., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that an oral presentation will be presented at the European Society for Medical Oncology (ESMO) Conference on Saturday, Sept. 27, in Madrid, Spain.
ECYT
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
http://m.seekingalpha.com/news/1995895
european firms involved in inversions slump in response to U.S. plans to curb the deals
HZNP
Re: Farmas USA
NAVB
Reciben una subvención del Instituto Nacional contra el Cáncer de $1,67 millones para la investigación del cáncer de cuello de útero.
http://seekingalpha.com/news/1996065-navidea-snags-sbir-grant